Hormone Replacement Therapy And Breast Cancer View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

1993-1996

FUNDING AMOUNT

0 USD

ABSTRACT

Objectives. Although menopausal hormone replacement therapy (HRT) is widely recommended for treatment of menopausal symptoms and prevention of osteoporosis, its effects on the risk of breast cancer are not clear. Therefore we propose to conduct a population-based case-control study focusing on the associations of various HRT preparations with breast cancer. Sweden offers unique opportunities to study HRT and breast cancer because of its nationwide cancer registration, population registers, high participation rate in epidemiologic studies and widespread use of estrogen (estradiol and conjugated estrogens) and estrogen-progestin treatment. Specific aims. Specific hypotheses to be addressed include: 1) Treatment with potent estrogens causes an increased risk of breast cancer which is related to duration of use and latency since first use and which persists even when treatment has been discontinued. 2) Estradiol has a stronger adverse effect on breast cancer risks than conjugated estrogens. 3) Use of estrogen plus progestin increases the risk of breast cancer more than estrogen alone. Experimental design and methods. A nationwide population-based case- control study is proposed, building on the experience of the investigators in similar large-scale studies. Eligible as cases will be all Swedish females aged 50-74 years diagnosed with histopathologically confirmed invasive breast cancer during the study period. Over 18 months, approximately 4,250 incident cases will be diagnosed and notified to the Cancer Epidemiology Unit. Controls will be selected - stratified by 5-year age group - from a national population register to form a control group of similar size as the case group. A covering letter, a questionnaire and a booklet with color photographs of all HRT brands used in Sweden will be mailed to all potential cases and controls. Reminders by mail and complementary telephone interviews are anticipated to provide at least an 80% participation rate among controls and 80% among cases, i.e. 3,400 cases and 3,400 controls. At the age of 60 years or more, 18- 20% of the controls are estimated to be ever users of HRT and 50% of these women will have used combined estrogen progestin treatment. This exposure frequency in the study population would yield an 80% power (alpha = 0.05, two-tailed) to detect a 20% - and a 99% power to detect a 50% - or more increased risk of breast cancer among women ever exposed to estradiol or conjugated estrogens and similar power among ever users of estrogen-progestin in combination. The corresponding estimates by duration of combined treatment were 84% for each stratum of 1-6, 6-11 and 12+ years respectively. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=2099121

Related SciGraph Publications

  • 2013-04. A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-02. No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density in BREAST CANCER RESEARCH
  • 2012-01. The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-06. Coffee consumption modifies risk of estrogen-receptor negative breast cancer in BREAST CANCER RESEARCH
  • 2011-04. A combined analysis of genome-wide association studies in breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2010-12. A genome-wide association scan on estrogen receptor-negative breast cancer in BREAST CANCER RESEARCH
  • 2010-04. Effects of childhood body size on breast cancer tumour characteristics in BREAST CANCER RESEARCH
  • 2010-04. Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer in BREAST CANCER RESEARCH
  • 2009-05. Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy? in BRITISH JOURNAL OF CANCER
  • 2008-12. The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer in BREAST CANCER RESEARCH
  • 2006-02. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study in BREAST CANCER RESEARCH
  • 2005-12. Survival after hip fracture in OSTEOPOROSIS INTERNATIONAL
  • 2004-11. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women in EUROPEAN JOURNAL OF EPIDEMIOLOGY
  • 2001-04. Cigarette Smoking, Alcohol Consumption, and Endometrial Cancer Risk: A Population-based Study in Sweden in CANCER CAUSES & CONTROL
  • 2000-11. Physical activity and postmenopausal endometrial cancer risk (Sweden) in CANCER CAUSES & CONTROL
  • 2000-07. Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden) in CANCER CAUSES & CONTROL
  • 2000-02. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden) in CANCER CAUSES & CONTROL
  • 1999-11. Differences in Risk Factor Patterns Between Cervical and Trochanteric Hip Fractures in OSTEOPOROSIS INTERNATIONAL
  • 1999-07. Use of oral contraceptives and endometrial cancer risk (Sweden) in CANCER CAUSES & CONTROL
  • 1998-11. Variation in the Efficacy of Hormone Replacement Therapy in the Prevention of Hip Fracture in OSTEOPOROSIS INTERNATIONAL
  • 1998-05. Association of Family History and Other Risk Factors with Breast Cancer Risk (Sweden) in CANCER CAUSES & CONTROL
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "0"
        }, 
        "description": "Objectives. Although menopausal hormone replacement therapy (HRT) is widely recommended for treatment of menopausal symptoms and prevention of osteoporosis, its effects on the risk of breast cancer are not clear. Therefore we propose to conduct a population-based case-control study focusing on the associations of various HRT preparations with breast cancer. Sweden offers unique opportunities to study HRT and breast cancer because of its nationwide cancer registration, population registers, high participation rate in epidemiologic studies and widespread use of estrogen (estradiol and conjugated estrogens) and estrogen-progestin treatment. Specific aims. Specific hypotheses to be addressed include: 1) Treatment with potent estrogens causes an increased risk of breast cancer which is related to duration of use and latency since first use and which persists even when treatment has been discontinued. 2) Estradiol has a stronger adverse effect on breast cancer risks than conjugated estrogens. 3) Use of estrogen plus progestin increases the risk of breast cancer more than estrogen alone. Experimental design and methods. A nationwide population-based case- control study is proposed, building on the experience of the investigators in similar large-scale studies. Eligible as cases will be all Swedish females aged 50-74 years diagnosed with histopathologically confirmed invasive breast cancer during the study period. Over 18 months, approximately 4,250 incident cases will be diagnosed and notified to the Cancer Epidemiology Unit. Controls will be selected - stratified by 5-year age group - from a national population register to form a control group of similar size as the case group. A covering letter, a questionnaire and a booklet with color photographs of all HRT brands used in Sweden will be mailed to all potential cases and controls. Reminders by mail and complementary telephone interviews are anticipated to provide at least an 80% participation rate among controls and 80% among cases, i.e. 3,400 cases and 3,400 controls. At the age of 60 years or more, 18- 20% of the controls are estimated to be ever users of HRT and 50% of these women will have used combined estrogen progestin treatment. This exposure frequency in the study population would yield an 80% power (alpha = 0.05, two-tailed) to detect a 20% - and a 99% power to detect a 50% - or more increased risk of breast cancer among women ever exposed to estradiol or conjugated estrogens and similar power among ever users of estrogen-progestin in combination. The corresponding estimates by duration of combined treatment were 84% for each stratum of 1-6, 6-11 and 12+ years respectively.", 
        "endDate": "1996-08-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2471355", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2471355"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "R01CA058427"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "strata", 
          "control group", 
          "women", 
          "age groups", 
          "similar power", 
          "breast cancer", 
          "case group", 
          "users", 
          "treatment", 
          "population register", 
          "reminder", 
          "invasive breast cancer", 
          "nationwide population", 
          "potential cases", 
          "estradiol", 
          "duration", 
          "investigators", 
          "estrogen", 
          "first use", 
          "case-control study", 
          "menopausal symptoms", 
          "age", 
          "national population", 
          "similar size", 
          "nationwide cancer registration", 
          "Swedish females", 
          "estimates", 
          "Controls", 
          "menopausal hormone replacement therapy", 
          "estrogen-progestin treatment", 
          "control", 
          "prevention", 
          "latency", 
          "unique opportunity", 
          "Sweden", 
          "epidemiologic studies", 
          "specific hypotheses", 
          "hormone replacement therapy", 
          "breast cancer risk", 
          "covering letter", 
          "effect", 
          "incident cases", 
          "experimental design", 
          "risk", 
          "participation rate", 
          "potent estrogen", 
          "estrogen-progestin", 
          "experience", 
          "months", 
          "case- control study", 
          "OBJECTIVE", 
          "widespread use", 
          "METHODS", 
          "questionnaire", 
          "Cancer Epidemiology Unit", 
          "study population", 
          "HRT brands", 
          "osteoporosis", 
          "specific aim", 
          "color photographs", 
          "booklet", 
          "study period", 
          "power", 
          "cases", 
          "exposure frequency", 
          "years", 
          "high participation rate", 
          "association", 
          "estrogen progestin treatment", 
          "similar large-scale studies", 
          "combination", 
          "mail", 
          "various HRT preparations", 
          "two-tailed", 
          "complementary telephone interviews", 
          "use", 
          "population", 
          "strong adverse effect"
        ], 
        "name": "HORMONE REPLACEMENT THERAPY AND BREAST CANCER", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.8993.b", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.8993.b", 
              "name": "UPPSALA UNIVERSITY", 
              "type": "Organization"
            }, 
            "familyName": "ADAMI", 
            "givenName": "HANS-OLOV", 
            "id": "sg:person.016525067377.55", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.016525067377.55", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2471355"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T12:13", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_6.xml.gz", 
        "startDate": "1993-09-08T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=2099121"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2471355'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2471355'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2471355'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2471355'


     

    This table displays all metadata directly associated to this object as RDF triples.

    122 TRIPLES      19 PREDICATES      100 URIs      92 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2471355 schema:about anzsrc-for:2211
    2 schema:amount Nd65729c2131b49969f2af27353f1b5c6
    3 schema:description Objectives. Although menopausal hormone replacement therapy (HRT) is widely recommended for treatment of menopausal symptoms and prevention of osteoporosis, its effects on the risk of breast cancer are not clear. Therefore we propose to conduct a population-based case-control study focusing on the associations of various HRT preparations with breast cancer. Sweden offers unique opportunities to study HRT and breast cancer because of its nationwide cancer registration, population registers, high participation rate in epidemiologic studies and widespread use of estrogen (estradiol and conjugated estrogens) and estrogen-progestin treatment. Specific aims. Specific hypotheses to be addressed include: 1) Treatment with potent estrogens causes an increased risk of breast cancer which is related to duration of use and latency since first use and which persists even when treatment has been discontinued. 2) Estradiol has a stronger adverse effect on breast cancer risks than conjugated estrogens. 3) Use of estrogen plus progestin increases the risk of breast cancer more than estrogen alone. Experimental design and methods. A nationwide population-based case- control study is proposed, building on the experience of the investigators in similar large-scale studies. Eligible as cases will be all Swedish females aged 50-74 years diagnosed with histopathologically confirmed invasive breast cancer during the study period. Over 18 months, approximately 4,250 incident cases will be diagnosed and notified to the Cancer Epidemiology Unit. Controls will be selected - stratified by 5-year age group - from a national population register to form a control group of similar size as the case group. A covering letter, a questionnaire and a booklet with color photographs of all HRT brands used in Sweden will be mailed to all potential cases and controls. Reminders by mail and complementary telephone interviews are anticipated to provide at least an 80% participation rate among controls and 80% among cases, i.e. 3,400 cases and 3,400 controls. At the age of 60 years or more, 18- 20% of the controls are estimated to be ever users of HRT and 50% of these women will have used combined estrogen progestin treatment. This exposure frequency in the study population would yield an 80% power (alpha = 0.05, two-tailed) to detect a 20% - and a 99% power to detect a 50% - or more increased risk of breast cancer among women ever exposed to estradiol or conjugated estrogens and similar power among ever users of estrogen-progestin in combination. The corresponding estimates by duration of combined treatment were 84% for each stratum of 1-6, 6-11 and 12+ years respectively.
    4 schema:endDate 1996-08-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
    6 schema:identifier N34f5eff984d945d38acda50caf0e8f47
    7 Nf0196944746c42bfa9b2136f5123c552
    8 schema:inLanguage en
    9 schema:keywords Cancer Epidemiology Unit
    10 Controls
    11 HRT brands
    12 METHODS
    13 OBJECTIVE
    14 Sweden
    15 Swedish females
    16 age
    17 age groups
    18 association
    19 booklet
    20 breast cancer
    21 breast cancer risk
    22 case group
    23 case- control study
    24 case-control study
    25 cases
    26 color photographs
    27 combination
    28 complementary telephone interviews
    29 control
    30 control group
    31 covering letter
    32 duration
    33 effect
    34 epidemiologic studies
    35 estimates
    36 estradiol
    37 estrogen
    38 estrogen progestin treatment
    39 estrogen-progestin
    40 estrogen-progestin treatment
    41 experience
    42 experimental design
    43 exposure frequency
    44 first use
    45 high participation rate
    46 hormone replacement therapy
    47 incident cases
    48 invasive breast cancer
    49 investigators
    50 latency
    51 mail
    52 menopausal hormone replacement therapy
    53 menopausal symptoms
    54 months
    55 national population
    56 nationwide cancer registration
    57 nationwide population
    58 osteoporosis
    59 participation rate
    60 population
    61 population register
    62 potent estrogen
    63 potential cases
    64 power
    65 prevention
    66 questionnaire
    67 reminder
    68 risk
    69 similar large-scale studies
    70 similar power
    71 similar size
    72 specific aim
    73 specific hypotheses
    74 strata
    75 strong adverse effect
    76 study period
    77 study population
    78 treatment
    79 two-tailed
    80 unique opportunity
    81 use
    82 users
    83 various HRT preparations
    84 widespread use
    85 women
    86 years
    87 schema:name HORMONE REPLACEMENT THERAPY AND BREAST CANCER
    88 schema:recipient N46bf98baf4aa4df9a419944e24aeca60
    89 sg:person.016525067377.55
    90 https://www.grid.ac/institutes/grid.8993.b
    91 schema:sameAs https://app.dimensions.ai/details/grant/grant.2471355
    92 schema:sdDatePublished 2019-03-07T12:13
    93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    94 schema:sdPublisher N0044faa56a9c4f89b1c89002f22bd096
    95 schema:startDate 1993-09-08T00:00:00Z
    96 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=2099121
    97 sgo:license sg:explorer/license/
    98 sgo:sdDataset grants
    99 rdf:type schema:MonetaryGrant
    100 N0044faa56a9c4f89b1c89002f22bd096 schema:name Springer Nature - SN SciGraph project
    101 rdf:type schema:Organization
    102 N34f5eff984d945d38acda50caf0e8f47 schema:name dimensions_id
    103 schema:value 2471355
    104 rdf:type schema:PropertyValue
    105 N46bf98baf4aa4df9a419944e24aeca60 schema:member sg:person.016525067377.55
    106 schema:roleName PI
    107 rdf:type schema:Role
    108 Nd65729c2131b49969f2af27353f1b5c6 schema:currency USD
    109 schema:value 0
    110 rdf:type schema:MonetaryAmount
    111 Nf0196944746c42bfa9b2136f5123c552 schema:name nih_id
    112 schema:value R01CA058427
    113 rdf:type schema:PropertyValue
    114 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    115 rdf:type schema:DefinedTerm
    116 sg:person.016525067377.55 schema:affiliation https://www.grid.ac/institutes/grid.8993.b
    117 schema:familyName ADAMI
    118 schema:givenName HANS-OLOV
    119 rdf:type schema:Person
    120 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
    121 https://www.grid.ac/institutes/grid.8993.b schema:name UPPSALA UNIVERSITY
    122 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...